Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Eisai Inc.
BeiGene
City of Hope Medical Center
Columbia University
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
National Institutes of Health Clinical Center (CC)
University of Nebraska
University of Nebraska
Columbia University
Stanford University
Atara Biotherapeutics
Karyopharm Therapeutics Inc
Ludwig Institute for Cancer Research
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Soligenix
Alexion Pharmaceuticals, Inc.
Rochester Skin Lymphoma Medical Group, PLLC
Roswell Park Cancer Institute
Eisai Inc.
Galderma R&D
Takeda
M.D. Anderson Cancer Center
Eli Lilly and Company
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Mayo Clinic
Helsinn Therapeutics (U.S.), Inc
Fred Hutchinson Cancer Center
Rhizen Pharmaceuticals SA
Roswell Park Cancer Institute
Bausch Health Americas, Inc.
Celgene
Roswell Park Cancer Institute
Mayo Clinic
Mayo Clinic
Abramson Cancer Center at Penn Medicine
University of Chicago
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute